Lichen China
LICN
4 hedge funds and large institutions have $242K invested in Lichen China in 2026 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
100% more funds holding
Funds holding: 2 → 4 (+2)
67% more capital inflows, than outflows
Capital inflows: $231K | Capital outflows: $138K
0.44% more ownership
Funds ownership: 1.03% → 1.47% (+0.44%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marex Group
London,
|
+$96.7K |
| 2 |
Jane Street
New York
|
+$93.7K |
| 3 |
Two Sigma Investments
New York
|
+$40.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$107K |
| 2 |
Virtu Financial
New York
|
-$31K |
LICN Hedge Fund Activity: Q3 2026 in Review
4 of the 8,221 institutional investors tracked by Wall St. Rank reported a position in Lichen China (LICN) for Q3 2026, worth a combined $242K — up 47% from $165K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new LICN positions and 1 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Marex Group, opening a new position worth an estimated $96.7K. The largest seller was UBS Group, cutting an estimated $107K.
- 4 institutional investors held Lichen China (LICN) as of Q3 2026, up from 2 in Q2 2026.
- Funds reported $242K of Lichen China stock for Q3 2026, up 47% quarter-over-quarter.
- 3 funds opened new Lichen China positions in Q3 2026 and 1 closed out, a net change of +2 holders.
- The largest Lichen China buyer in Q3 2026 was Marex Group, an estimated $96.7K added.
- The largest Lichen China seller in Q3 2026 was UBS Group, an estimated $107K sold.
Based on aggregated 13F filings for Q3 2026.